Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $199.62B.
ENTERPRISE VALUE (EV)
$199.62B
Gilead Sciences, Inc.
Market Cap
$182.25B
Enterprise Value (EV)
$199.62B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Gilead Sciences, Inc. (GILD) | $182.25B | $199.62B |
| Abbott Laboratories (ABT)vs › | $182.82B | $214.94B |
| Novo Nordisk A/S (NVO)vs › | $200.83B | $216.42B |
| Pfizer Inc. (PFE)vs › | $158.53B | $220.89B |
| Amgen Inc. (AMGN)vs › | $213.09B | $279.29B |
| Danaher Corporation (DHR)vs › | $144.95B | $168.19B |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.62B | $264.27B |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.35B | $130.07B |
| Bristol-Myers Squibb Company (BMY)vs › | $132.30B | $170.89B |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.94B | $124.32B |
Market Cap
$182.25B
Total Debt
$24.94B
Cash
$7.56B
Enterprise Value
$199.62B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
